Surmodics (SRDX) Stock Price, News & Analysis

Company Overview

Surmodics, Inc. (NASDAQ: SRDX) is a medical technology company specializing in surface modification and drug-eluting coating technologies for medical devices and in vitro diagnostic applications. The company’s core expertise lies in polymer-based solutions that enhance device performance, including hydrophilic coatings to improve catheter lubricity and drug-delivery coatings for cardiovascular and peripheral vascular stents. Surmodics also offers proprietary diagnostic assay platforms and automation solutions for clinical laboratories.

Surmodics’ product portfolio is organized around two main segments: medical device and in vitro diagnostics. In the medical device segment, the company provides therapeutic delivery coatings, surface modifiers, and adhesive technologies for customers developing implants, guide wires, and catheters. On the diagnostics side, Surmodics supplies reagents, assay calibrators, and control materials, as well as instrumentation used in immunoassay and molecular diagnostic workflows.

Founded in Eden Prairie, Minnesota, in 1986, Surmodics has expanded its operations to serve a global client base across North America, Europe, and Asia. The company’s research and development efforts focus on advancing biocompatible polymers and next-generation delivery systems, while its manufacturing facilities adhere to international quality standards. Surmodics collaborates with a diverse set of medical device OEMs, contract manufacturers, and diagnostic companies to bring customized surface and assay solutions to market.

Surmodics is led by President and Chief Executive Officer Richard Carlin, who has overseen strategic partnerships and product launches since taking the helm in 2016. The company maintains a governance structure aimed at innovation and regulatory compliance, with a board comprised of directors experienced in medical technology, life sciences, and global business operations. Through ongoing investment in R&D and customer-driven development, Surmodics seeks to address clinical challenges and improve patient outcomes worldwide.

Key Stats

• Today's Range: $33.14 to $33.90
• 50-Day Range: $28.81 to $38.00
• 52-Week Range: $26.00 to $40.38
• Volume: 199,386 shs
• Average Volume: 193,808 shs
• Market Capitalization: $477.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Hold

Surmodics Stock Analysis - MarketRank™

Surmodics scored higher than 89% of companies evaluated by MarketBeat, and ranked 124th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Surmodics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Surmodics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 300.00%

Earnings Growth

Earnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surmodics is -27.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surmodics is -27.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Surmodics has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.05% of the float of Surmodics has been sold short.

Short Interest Ratio / Days to Cover

Surmodics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surmodics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surmodics does not currently pay a dividend.

Dividend Growth

Surmodics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.52

Percentage of Shares Shorted

3.05% of the float of Surmodics has been sold short.

Short Interest Ratio / Days to Cover

Surmodics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surmodics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.71

News Sentiment

Surmodics has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Surmodics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for SRDX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surmodics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.90% of the stock of Surmodics is held by insiders.

Percentage Held by Institutions

96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRDX Stock Analysis - Frequently Asked Questions

How have SRDX shares performed this year?

Surmodics' stock was trading at $39.60 on January 1st, 2025. Since then, SRDX shares have decreased by 15.7% and is now trading at $33.39.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) announced its quarterly earnings data on Friday, August, 8th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.27. The business earned $29.57 million during the quarter, compared to analyst estimates of $28.04 million. Surmodics had a negative trailing twelve-month return on equity of 2.99% and a negative net margin of 14.59%.

Who are Surmodics' major shareholders?

Surmodics' top institutional investors include Alliancebernstein L.P. (5.95%), Gabelli Funds LLC (2.90%), Hudson Bay Capital Management LP (2.80%) and Hudson Bay Capital Management LP (2.80%). Insiders that own company stock include Timothy J Arens, David Dantzker, Ronald B Sr Kalich Sr and Jose H Bedoya.
View institutional ownership trends.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/04/2025
• Fiscal Year End: 9/30/2025
• Next Earnings (Estimated): 11/05/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:SRDX
• CIK: 924717
• Web: www.surmodics.com
• Phone: (952) 500-7000
• Fax: 952-500-7001
• Employees: 450
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Surmodics: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +26.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 170.15
• P/E Growth: N/A
• Net Income: -$11.54 million
• Net Margins: -14.59%
• Pretax Margin: -12.16%
• Return on Equity: -2.99%
• Return on Assets: -1.99%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 3.91
• Quick Ratio: 3.10

Sales & Book Value

• Annual Sales: $120.80 million
• Price / Sales: 4.03
• Cash Flow: $0.31 per share
• Price / Cash Flow: 110.03
• Book Value: $7.79 per share
• Price / Book: 4.37

Miscellaneous

• Outstanding Shares: 14,298,000
• Free Float: 13,025,000
• Market Cap: $486.56 million
• Optionable: Optionable
• Beta: 1.37